Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test may spot hidden blood vessel damage in kids with growth issues

NCT ID NCT03422081

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at whether a blood test for a substance called ADMA can measure blood vessel health in children with growth hormone deficiency or those born small for their age. Researchers compared ADMA levels to ultrasound measurements of artery function in 23 children. The goal was to find a simpler way to detect early blood vessel problems in these children.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to check blood vessel health in children with growth disorders.
What could go wrong
This was a small, early study with only 23 participants, so results may not apply to all children. The test is not yet proven for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

23 people

The number who actually took part.

Started

Jun 2014

Finished

Dec 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

pediatric patients with growth disorders and matched control children

Ages

3 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Group A: GHD, defined by 2 GH peaks less than 6.6 ng/ml (20 mU/L) at two stimulation tests * Group B: IUGR, defined by a birth length and/or a birth weight inferior to - 2 SD for gestational age according to Usher and McLean charts * Group C: Control children matched to children matched to subjects of groups A and B, according to gender and age * Informed consent signed by representative of the parental authority Exclusion Criteria: * Chronic disabling disease (ex: diabetes, severe asthma) * Evolving cancer * Severe psychiatric disorder (ex: autism, schizophrenia; severe depression) * Hypothalamic tumor (ex: craniopharyngioma) * Anamnesis of cranial irradiation * Overweight, obesity or thinness * Precocious puberty * Non-replacing therapy by glucocorticoids or sex steroids less than 1 month before the exploration * Anterior treatment by recombinant human GH * Other conditions, treatments or habits impacting arterial reactivity: acrocyanosis, cryoglobulinemia, beta adrenergic blocking habits, tobacco smoking or other drug addictions, dyslipidemia * Pregnancy or lactation * Acute infection less than three weeks before the investigation * Participation to a therapeutic protocol * Impossibility for the representatives of the parental authority to understand the objectives of the protocol * Absence of social security coverage. Refusal by the parents to sign the informed consent or oral refusal by the child to participate to the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Growth hormone deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fetal growth restriction isolated congenital growth hormone deficiency pituitary dwarfism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Growth hormone deficiency Small for gestational age

Contacts and locations

Locations

  • CHU Purpan

    Toulouse, France

  • Hôpital Jeanne de Flandre - CHRU de Lille

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.